Technology

Artificial Intelligence Big Data Cloud Computing Cyber Security Data Management Electronics Enterprise & Network Technology Financial Technology Hardware Mobile & Wireless Nanotechnology Semiconductor Software Telecommunications
News Release Digital Asset Direct

The Growing Opportunity in Agricultural Drones: Four Stocks to Watch in Precision Ag

ZENA

The agriculture drone market is exploding. Valued at 6.1 billion dollars in 2024, it is expected to nearly quadruple to 23.8 billion dollars by 2032, growing at a compound annual rate of 18.5 percent. This rapid expansion is driven by rising demand for precision farming tools that improve efficiency, reduce chemical use, and increase crop yields. Advances in drone technology, AI, and supportive regulations are making drone-powered crop monitoring, spraying, and data analysis practical and cost-effective for farms of all sizes. With such strong growth underway, it makes sense to pay attention to companies leading the charge in agricultural drones. Let’s look at four stocks worth watching in this fast-moving sector. ZenaTech, Inc. (Nasdaq: ZENA) is positioning itself as a leading force in the precision agriculture drone market by combining autonomous drone hardware with advanced AI software and a scalable Drone as a Service business model. Its wholly owned subsidiary, ZenaDrone, designs and manufactures multifunction drones used across agriculture, defense, logistics, and inspection sectors. ZenaTech’s flagship agricultural drone, the ZenaDrone 1000, is a medium-sized vertical takeoff and landing (VTOL) quadcopter capable of lifting up to 40 kilograms. The platform recently received FAA Part 137 approval, allowing the company to commercially conduct crop spraying operations—including pesticides, herbicides, fungicides, fertilizers, and seed distribution—across the United States. This regulatory milestone unlocks significant domestic revenue potential while paving the way for expansion into Europe. CEO Shaun Passley, Ph.D., commented, “FAA Part 137 approval now enables our team to finish final testing and commence sales of our agriculture solutions. Drones offer a more precise, efficient, cost-effective, and safer alternative to traditional methods.” ZenaTech’s Drone as a Service (DaaS) model offers flexible subscription and pay-per-use options, giving farmers access to drone technology without the upfront investment, pilot certification, or regulatory burden. In May 2025, the company opened a European headquarters in Dublin, Ireland, to support its agricultural drone operations in a market projected to grow at 28.6 percent annually and reach $43.2 billion by 2032, according to Market Data Forecast. Passley added, “The expansion of our Dublin office marks a new chapter in our strategy to scale our drones and DaaS offerings globally while servicing the fastest-growing agricultural drone markets located in Europe.” Beyond agriculture, ZenaTech has acquired six U.S. companies to strengthen its drone-enabled services in land surveying and powerline inspection. These moves create operational synergies across verticals and accelerate adoption of its autonomous platforms. With the global agriculture drone market expected to grow from $6.1 billion in 2024 to $23.78 billion by 2032, ZenaTech is well positioned to capitalize through its FAA-certified hardware, expanding DaaS footprint, and international rollout. AgEagle Aerial Systems (NYSE: UAVS) has been a precision agriculture and unmanned aerial systems (UAS) pioneer since its founding in 2010. The company designs and delivers professional-grade fixed-wing drones, sensors, and software solutions serving customers in agriculture, energy, construction, and government. In Q1 2025, UAVS reported net income of $7.06 million, reversing a $6.32 million loss from the prior year. Gross margin improved to 58.5 percent from 50.2 percent, while operating expenses fell nearly 28 percent—reflecting stronger execution, increased drone sales, and financial discipline. The company has remained active on the regulatory front, participating in FAA discussions around Rule Part 108, which could enable broader Beyond Visual Line of Sight (BVLOS) operations. CEO Bill Irby emphasized that this regulatory evolution will unlock more commercial drone use across agriculture and other industries. Technologically, UAVS partnered with Ascent AeroSystems to integrate the RedEdge-P multispectral camera into the rugged Spirit UAV platform—enhancing precision and efficiency for farm applications. It also teamed up with India-based Vyom Drones to license manufacturing and expand into one of the world’s fastest-growing agricultural drone markets. With a return to profitability, regulatory momentum, and new strategic partnerships, AgEagle is well positioned to ride the accelerating growth of drone-enabled agriculture. Investors looking for scale in precision agriculture might also consider CNH Industrial (NYSE: CNH), a global machinery leader integrating automation across tractors, sprayers, and harvesters. Through brands like Case IH and New Holland, CNH is deploying AI-driven spraying systems and sensor-laden harvesters to optimize crop inputs and yields. While Q1 results reflected soft demand—with revenue down 21 percent and ag EBIT off 64 percent—the company’s ongoing tech innovation and global footprint suggest potential upside once the cycle turns. Meanwhile, AeroVironment (NASDAQ: AVAV) provides exposure to drone systems from a national security angle. With $820.6 million in 2025 revenue and $1.2 billion in bookings, AVAV maintains a strong backlog. However, its agricultural exposure is minimal, and its recent $750 million equity raise may weigh on short-term performance. As agricultural innovation accelerates, the market is shifting toward platforms that combine autonomy, analytics, and accessibility. While industrial giants and defense players bring scale, focused firms like ZenaTech and AgEagle are delivering end-to-end precision agriculture solutions purpose-built for this moment. For investors seeking exposure to one of the fastest-growing applications of drone technology, these names offer compelling, targeted entry points. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by the company to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com

July 02, 2025 07:00 AM Eastern Daylight Time

News Release

Wall Street Analyst Issues Bullish Update on DarioHealth, Reiterates $3 Price Target Highlighting 320% Upside Potential (NASDAQ: DRIO)

Alpha Catalyst

Wall Street analyst Theodore O'Neill of Litchfield Hills Research has reiterated his Buy rating and $3 price target on DarioHealth Corp. (NASDAQ: DRIO)*, highlighting what he sees as significant upside potential of approximately 320% from current trading levels around $0.71. The analyst's updated note comes as recently IPO’d competitor Hinge Health (NYSE: HNGE) currently trades at a $3.53 billion market cap following its successful public debut, creating what O'Neill describes as a stark "valuation gap" with DarioHealth, which has a market capitalization of approximately $31 million despite comparable growth metrics and superior gross margins. GLP-1 Success Validates Platform's Value Proposition The research update particularly emphasized DarioHealth's recent clinical findings presented at the American Diabetes Association's 85th Annual Scientific Sessions. A landmark study of 715 GLP-1 users revealed that patients who discontinued their medication maintained stable outcomes with no significant weight or glucose rebound for at least six months when using Dario's platform. The analyst's report highlights DarioHealth's study findings that demonstrated users who discontinued GLP-1 medication while continuing to use the platform maintained stable outcomes without significant weight or glucose rebound for at least six months. O'Neill points to these clinical results as a key differentiator for the company's value proposition in the expanding GLP-1 market. This clinical validation comes at a critical time as the GLP-1 market for weight loss medications is projected to reach $100 billion by 2030, with employers increasingly struggling to manage the high costs of these drugs while ensuring sustainable patient outcomes. Strategic Partnerships Expand Addressable Market The analyst also highlighted DarioHealth's recent strategic commercial agreement with GreenKey Health announced on June 26, which targets the $150 billion sleep apnea market affecting over 29 million Americans. The collaboration integrates behavioral health, sleep, and cardiometabolic care to deliver a comprehensive solution for employers and health plans seeking to reduce healthcare costs. O'Neill's analysis emphasizes the strategic benefits of DarioHealth's partnership with GreenKey Health, noting how the collaboration combines their respective strengths to create a comprehensive, data-driven solution designed to improve health outcomes, reduce costs, and boost productivity for employers and health plans. Dramatic Valuation Discount Compared to Peers The most compelling aspect of the analyst's thesis is the dramatic valuation contrast between DarioHealth and its peers. Using a discounted future earnings model and comparative peer analysis, O'Neill calculates a fair value of $3 per share. According to the report, If DarioHealth were to trade at this target, its Market Cap/Sales multiple would be approximately 2.2x, which would still be below the peer average of 2.38x, according to the analyst's calculations. This suggests the company remains significantly undervalued even at the target price, especially considering its high growth profile and improving gross margins. The company's B2B2C gross margins now exceed 80%, higher than many competitors, while operating expenses have declined significantly, positioning the company on a path to operational cash flow breakeven by the end of 2025. Financial Outlook Supports Bullish Thesis O'Neill forecasts DarioHealth could reach $35.9 million in revenue for 2025, growing to $66.1 million in 2026, with the company expected to achieve GAAP profitability during 2026. DarioHealth's AI-driven platform serves five chronic conditions through a single interface, diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health, giving it one of the most comprehensive offerings in the industry and positioning it to capitalize on employer and payer trends toward vendor consolidation. As digital health platforms continue to gain traction and the GLP-1 market expands, O'Neill believes DarioHealth remains positioned for potential significant share price appreciation as the market recognizes its comparable business metrics relative to recently validated competitors. ‎ ‎ ‎ This post was originally published on AlphaCatalyst ‎ ‎ Recent News Highlights from Dario Dario and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings DarioHealth Reports First Quarter 2025 Financial and Operating Results ‎ ‎ ‎ * Paid Advertisement: This content is a paid advertisement. The Author, Wall Street Wire, has received compensation from DarioHealth Corp for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. We are not responsible for any price targets or market size estimates that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details ‎ media.globalmarkets@gmail.com

July 02, 2025 05:46 AM Eastern Daylight Time

ALLIES OF SKIN PARTNERS WITH MINDFULNESS EXPERT AND BEST-SELLING AUTHOR CASE KENNY FOR “SKINCARE = SELF-CARE” CAMPAIGN

Allies of Skin

Allies of Skin, the supercharged clinical skincare brand founded by Nicolas Travis, announces its partnership with mindfulness expert and best-selling author Case Kenny to celebrate the connection between skincare and self-care. Renowned for its results-driven routines, personally curated by Nicolas Travis from the brand’s assortment of supercharged clinical skincare, Allies of Skin is taking skincare one step further. Together with Case Kenny, they introduce a powerful perspective: skincare as self-affirmation. Allies of Skin's iconic routines are sealed with a bespoke affirmation created by Case Kenny – restoring the skin while reconnecting you with your sense of self. The collaboration invites consumers to turn their daily regimens into powerful acts of self-connection, blending high-performance formulas with holistic wellness. Affirmations aren’t just an add-on – they're the final, essential step in any skincare routine. Just as an Allies of Skin product seals in skincare benefits, a self-affirmation seals in intention. Great skin has the power to make you feel better – more confident, more centered, and more connected to yourself. Together, Nicolas Travis and Case Kenny are lighting both the inner and outer light for consumers, redefining skincare as a ritual for total well-being. For the collaboration and as an official #ALLIESPartner, Case Kenny will curate bespoke digital affirmation cards which will be available through social “drops,” lead engaging social content centered around mindfulness, skincare, and self-love, host events aimed at building conscious community, and participate in a co-branded influencer seeding to spread the message that skincare equals self-care. FROM THE FOUNDER "It has taken 18 years for me to appreciate the beauty of the scars from my experience with facial necrosis. Through my own healing journey, I discovered Case Kenny and his brilliant work. His words resonate with me on a soul level, and they serve as guiding light on dark days. It is this light that I hope to share with our allies. The unwavering light that comes with being at home in your skin. The light that radiates from within when you are at peace with yourself and your journey. The light that no person or situation can diminish. It’s time for all of us to shine a little brighter," says Nicolas Travis, Founder of Allies of Skin. FROM CASE KENNY "I’m very excited to partner with Allies of Skin because we share the same belief: the light you carry comes from what you’ve healed. I believe the darkness you endure in life only makes your light shine brighter, and Allies of Skin believes the same. They believe that skincare isn’t just about how you look, but how you feel. That how you care for yourself on the outside is a reflection of the self-respect, growth, and peace you’re building within. That your outer glow is a mirror of your inner work. What I love most is their mission to make skincare more human - to honor the ups and downs, to embrace the imperfections, and to remind us that showing up for yourself is enough. That kind of alignment is meaningful," says Case Kenny. To stay updated on drops, events, and inspiration, follow @alliesofskin and @casekenny on Instagram. ABOUT ALLIES OF SKIN Allies of Skin redefines skincare with a “supercharged clinical” approach, maximizing clinically proven actives, protective antioxidants, and supporting the skin barrier. Founded by Nicolas Travis in 2016, the high-performance formulas deliver visible, transformative results in fewer steps, with innovative active ingredients like Epidermal Growth Factors (GF), Copper Tripeptide, and patented Encapsulated Retinaldehyde (Retinal), with the mission of delivering unparalleled skin regeneration and longevity. Contact Details OGAKI Digital Hallie Sawyer +1 818-388-7338 hsawyer@ogakidigital.com Company Website https://us.allies.shop/

July 01, 2025 05:24 PM Eastern Daylight Time

Kraken Elected as Super Representative on the TRON Network

TRON DAO

Geneva, Switzerland, July 1, 2025 – TRON DAO, the community-governed DAO dedicated to accelerating the decentralization of the internet through blockchain technology and decentralized applications (dApps), today announced that Kraken, one of the world’s longest-standing and most secure crypto platforms, has been elected as a Super Representative (SR) on the TRON blockchain network. Kraken’s institutional-grade protocol staking infrastructure will bring security and reliability to TRON's decentralized governance by validating transactions and producing blocks. As a Super Representative, Kraken will help enhance the network's security and efficiency while enabling broader institutional participation in TRON’s incentive model. Kraken operates secure, performant, and cost-effective block production nodes for decentralized PoS protocols on behalf of institutional investors. Their multi-tier signing and listening node architecture delivers stakeholders the ideal combination of security, scalability and decentralization. Kraken’s non-custodial staking infrastructure enables institutions to compound crypto assets through staking, offering automated payouts, detailed reporting, and a service-level agreement (SLA) designed to meet enterprise-grade reliability standards. “Kraken being elected as a Super Representative is a strong signal of growing institutional confidence in TRON’s network and governance model,” said Sam Elfarra, Community Spokesperson for TRON DAO. “Their participation helps strengthen the decentralized foundation of the TRON blockchain while also expanding access to secure, reliable staking infrastructure. As adoption of TRON continues to grow, institutional stakeholders are playing an increasingly important role in supporting a network designed for real-world utility, scale, and sustainable incentives.” “We’re proud to have been elected as a Super Representative on the TRON network,” said Jonathan Marcus, Head of Staked at Kraken. “As institutions continue to explore secure and efficient ways to participate in blockchain ecosystems, TRON stands out for its scale, reliability, and growing global adoption. We look forward to supporting TRON’s decentralized governance and providing the infrastructure that helps institutional stakeholders access meaningful rewards for contributing to the long-term strength of the network.” The TRON network is secured and governed by a decentralized group of SRs, including globally recognized institutions such as Google Cloud, Binance, OKX, P2P.org, Nansen, Luganodes, Kiln, and Abra. Their active participation reflects increasing institutional confidence in TRON’s infrastructure and its role in supporting scalable, secure, and transparent blockchain systems. Kraken’s election as a Super Representative highlights the growing institutional utility of the TRON network. With deep expertise in secure and reliable onchain staking, Kraken brings added confidence to institutions seeking to engage with decentralized systems. Their involvement reinforces TRON’s ability to support secure, scalable, and incentive-aligned blockchain activity across global markets. As institutional engagement with blockchain continues to evolve, TRON remains focused on building the infrastructure needed to support long-term adoption and real-world financial use cases. Read more about the Super Representatives, including Kraken, on TRONSCAN. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON blockchain has experienced significant growth since its MainNet launch in May 2018. TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin, exceeding $80 billion. As of May 2025, the TRON blockchain has recorded over 316 million in total user accounts, more than 10 billion in total transactions, and over $22 billion in total value locked (TVL), based on TRONSCAN. TRONNetwork | TRONDAO | X | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network About Kraken Kraken is one of the world’s longest-standing and most secure crypto platforms. Our mission is to accelerate the global adoption of crypto, so that everyone can achieve financial freedom and inclusion. Globally, Kraken clients trade more than 300 digital assets and 6 different national currencies, including GBP, EUR, USD, CAD, CHF, and AUD. Founded in 2011, Kraken was among the first to offer spot trading with margin, parachain auctions, staking, regulated derivatives and index services under one roof. With millions of individuals, traders and institutions around the world, Kraken offers professional 24/7/365 client support along with one of the fastest, most performant trading platforms available. Kraken has set the industry standard for transparency and client trust, and was the first crypto platform to conduct Proof of Reserves. Kraken markets can be monitored and traded via the web or through the Kraken and Kraken Pro iOS and Android apps. For more information about Kraken, please visit kraken.com. Media Contact Lauren Post press@kraken.com Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

July 01, 2025 10:24 AM Eastern Daylight Time

Image

Should More Pensions Adopt Tampa Police and Fire’s Pure Stock-Picking Approach? MPI Analysis Finds its Results Could Easily be Replicated through a More Diversified Approach Instead

Markov Processes Inc.

Markov Processes International, Inc. (“MPI”), a leading provider of investment technology, analytics, research and indices for the global investment management industry, today released significant institutional research analyzing the $3.2 billion City of Tampa Fire and Police Pension Fund that shows that the fund, long known for returns through a stock-picking approach uncommon in pensions and endowments, actually is a validation of the less risky principles of broader diversification and index investing. Tampa Fire and Police has been an outlier among pensions and endowments, using a single manager in Bowen, Hanes & Co., and employing an investment approach that relies heavily on selecting single stocks. Traditionally, pensions and endowments take a more diversified approach, and their investments follow Modern Portfolio Theory, which stresses the importance of diversification in managing risk. MPI’s study represents the first rigorous, data-driven examination of Bowen’s performance, offering quantitative clarity after decades of unchallenged praise and lingering doubts about its authenticity. MPI’s proprietary analysis, calculated using MPI’s Stylus Pro software, performed a returns-based analysis of performance of Tampa Fire and Police – which has notably outperformed or matched its benchmarks in nine of the last 10 years – and found that it could be replicated with a more diversified approach. Indeed, MPI’s Stylus Pro created a long-only portfolio of market indices which credibly (and predictively) mimics the fund’s return. “While the eye-popping stock-picking has made the managers at Bowen seem like modern-day Warren Buffetts, the truth is much more mundane and instructive for other institutional money managers,” said Michael Markov, Founder and Chief Executive Officer of MPI. “We know that once a portfolio reaches a certain size, individual stock picks blend into thematic exposures, like the "Magnificent Seven" tech stocks. Active managers spending their days on bottom-up research might rather want to concentrate on whether similar results could be obtained in less risky ways, such as through a basket of ETFs.” The analysis did show that Bowen’s approach did present moderately higher risk than other pensions and endowments, but it was only moderately higher than other equity-heavy public pensions. And, in terms of efficiency, the fund’s Sharpe ratio was better than its benchmark. Still, the findings of MPI’s analysis indicate that managers who base their diversified strategies on the Nobel-prize winning Modern Portfolio Theory have the potential to achieve similar returns, without having to hustle to pick the right stocks. “Diversification works,” Markov said. “Whether or not one believes in volatility or correlation matrices, our analysis validates what Modern Portfolio Theory suggested. There’s little true alpha left in managing a $3 billion liquid portfolio through stock-picking alone.” The full report can be found here. For additional information on MPI’s research or to get a demo of its Stylus Pro software, please contact MPI at +1 (908) 608-1558 or info@markovprocesses.com. About MPI Markov Processes International Inc. (MPI) is a leading provider of solutions for investment research, analysis and reporting to the global wealth and investment management industry. MPI works with more than 200 client organizations, including pensions and endowments, sovereign wealth funds, global wealth management firms, institutional consultants, regulators, investment advisors and asset managers. Rooted in the principles of transparency, objectivity, and efficiency, MPI takes an innovative approach to problem solving in the areas of fund analysis, risk management, asset allocation, and reporting to ensure that its clients have the tools to succeed in ever-more-crowded markets. Follow us on Twitter @MarkovMPI and connect with us on LinkedIn. Contact Details For MPI Ray Hennessey, Vocatus rh@vocatusllc.com Company Website https://www.markovprocesses.com/

July 01, 2025 09:00 AM Eastern Daylight Time

USDT on TRON Surpasses $80 Billion, Strengthening TRON’s Position as the Leading Stablecoin Network

TRON DAO

June 26, 2025 - Geneva, Switzerland - TRON DAO announced today that the total circulating supply of USDT on the TRON blockchain has exceeded $80 billion, further cementing TRON’s position as the top blockchain for USDT activity. With USDT holding more than 63 percent of the global stablecoin market and surpassing 155 billion dollars in circulation, over half of that supply is issued on TRON. Since January 2025, the supply of USDT issued on the TRON network has grown by approximately 20 billion, according to a data platform Token Terminal. TRON continues to lead all blockchain networks in USDT issuance, transaction volume, and daily user activity. TRON has established itself as the preferred settlement network for stablecoins, hosting around 60 percent of payment transaction volume. Its scale and efficiency continue to position it as the backbone for digital dollar movement across borders and diverse financial applications. As of June 2025, TRON processes over 8.9 million daily transactions and has surpassed 315 million total user accounts. Additionally, the network facilitates an average of $21.5 billion in daily USDT transfers. With over 1 million unique wallets transacting USDT each day, TRON also leads in active stablecoin wallet usage, representing 28 percent of global active addresses. With stablecoins playing an increasingly important role in cross-border settlement, financial access, and dollarization in emerging markets, TRON has established itself as one of the most widely used blockchain networks in the world. Its combination of scale, speed, and low transaction costs has made it the preferred environment for stablecoin activity worldwide. “TRON’s success is grounded in its alignment with the core values of crypto—openness, user empowerment, and real-world utility,” said Justin Sun, founder of TRON. “USDT on TRON has become the go-to choice for millions of people because it works—it’s fast, efficient, and easy to use. The TRON ecosystem remains focused on building reliable infrastructure for the next generation of digital finance.” TRON’s leadership in the stablecoin space continues to evolve to meet growing institutional demand. In April 2025, World Liberty Financial chose TRON to launch its USD1 stablecoin, which began minting earlier this month. Additionally, the TRON ecosystem has deepened its focus on financial compliance through the T3 Financial Crime Unit (T3 FCU), a joint initiative with Tether and TRM Labs. Since launch, T3 FCU has worked with law enforcement agencies worldwide to freeze over $160 million linked to illicit activity. As the digital dollar economy continues to expand, TRON remains a core pillar of the infrastructure driving greater efficiency and financial inclusion. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON blockchain has experienced significant growth since its MainNet launch in May 2018. TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin, exceeding $80 billion. As of June 2025, the TRON blockchain has recorded over 315 million in total user accounts, more than 10 billion in total transactions, and over $21 billion in total value locked (TVL), based on TRONSCAN. TRONNetwork | TRONDAO | X | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

June 26, 2025 12:46 PM Eastern Daylight Time

Image

Bonsai Launches Telemetry Platform to Connect All Farm Equipment — Autonomous or Not

Bonsai Robotics

Bonsai Robotics Inc. ("Bonsai"), a leading developer of agriculture AI solutions, announced the launch of its proprietary offering for building a transformative connected farming platform for high-value crops. The company’s software ecosystem, Teletrace ™, will expand from support of its fully autonomous machines to enabling conventional tractors and implements to be monitored and managed through the same digital interface. This new intelligent management solution is powered by the Topcon CL-55, a compact telemetry device that plugs directly into the existing CAN bus — a standard interface on most modern tractors and implements. With this connection, real-time machine data is transmitted via Topcon’s CloudLink service and seamlessly integrated into Bonsai’s cloud platform. Growers can monitor and manage every piece of equipment — new or old, autonomous or not — through a single, unified interface powered by Bonsai’s Teletrace ecosystem. “Bonsai’s mission is to bring the AI revolution to the field by unlocking the ability to reimagine how machines are built, deployed, and managed,” said Tyler Niday, CEO and co-founder of Bonsai. “Our solution is no longer limited to just autonomous equipment. Now, any farm machinery, regardless of make or vintage, can be transformed into a smart machine utilizing Teletrace allowing growers to manage mixed fleets from anywhere and track operational utilization, performance and metrics such as harvest rate, input usage and more.” Bonsai’s autonomy system is purpose-built for the harsh, variable conditions of orchard environments – where GPS, LiDAR, and satellite-based systems often fall short, and dust is a constant challenge. In addition, the company’s vision-based autonomy stack enables reliable operation under dense canopy, uneven terrain and without GPS dependency. With Teletrace, growers can now reduce operator error through digital job dispatching and smart implement control and prepare for phased autonomy adoption without the cost of full equipment upgrades. “Permanent crops have seen mechanical innovation, but not digital transformation,” Niday added. “We are here to change that. With Bonsai, the orchard is no longer an offline black hole of information, but now a connected, intelligent system.” This launch follows successful deployments across almonds, pistachios and citrus operations in California and Australia, where growers are using Bonsai to automate spraying, mowing, disking, shaking and sweeping— and now, to track and manage conventional equipment as well. The company’s long-term vision is to manage a diverse set of machines across brands, horsepower ranges, and autonomy levels from a single, intuitive platform. About Bonsai Robotics Bonsai Robotics Inc. is reimagining farming production systems with an AI-first approach to provide vision-based autonomous solutions for harsh environments. Based on patented AI models, a leading orchard data set and computer-vision software, Bonsai’s solutions integrate seamlessly to make OEM equipment operate autonomously. Bonsai technology can navigate in GNSS-denied environments, without a cellular or internet connection, making the highly affordable technology ideal for the toughest physical conditions where dust, darkness, debris, elevation changes and vibration may occur. Learn more at https://www.bonsairobotics.ai/ Contact Details Bonsai Media Contact: Erika Poppelreiter erika@soldiercreekcommunications.com

June 26, 2025 08:15 AM Pacific Daylight Time

Image

NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads

The Finance Herald

NeuroSense Therapeutics (NASDAQ: NRSN)* has completed a key pre-submission meeting with Health Canada for its ALS drug PrimeC, signaling potential upcoming eligibility for Canada’s fast-track approval pathway (NOC/c). The positive tone reported from the meeting could signal accelerated Canadian approval coming soon and could also potentially advance negotiations for the partnership with a global pharma player. With strong Phase 2b data and a potential $100–150M of peak revenue from Canadian market alone, this milestone could be a catalyst for regulatory momentum and investor revaluation. ‎ NeuroSense Therapeutics (NASDAQ: NRSN) may be nearing a turning point in its ALS drug development journey, and the market is starting to take notice. The Israeli biotech just disclosed that it held a pivotal pre-submission meeting with Health Canada for PrimeC, its lead ALS candidate, potentially setting the stage for both early approval and the finalization of a major pharma partnership. In a Form 6-K filed with the SEC, NeuroSense confirmed the completion of a pre-New Drug Submission (pre-NDS) meeting with regulators to explore eligibility for Canada’s fast-track approval mechanism, known as the Notice of Compliance with Conditions (NOC/c). The company described the discussion as “constructive” and left the meeting “highly encouraged”, language that signals regulatory alignment and opens the door for PrimeC to potentially Canadian patients much sooner than expected. For ALS patients in Canada—and a company with a current ~$52 million valuationm that kind of timeline could prove transformational. But the Health Canada development is more than just a regulatory checkpoint—it’s a potential trigger for something bigger. Back in December 2024, NeuroSense signed a binding term sheet with a global pharmaceutical company, covering full Phase 3 funding, upfront cash, milestone payments, and double-digit royalties. A positive signal from Canadian authorities could be the validation needed to cement that deal and set the stage for global expansion. PrimeC already has data to back up its ambitions. In its Phase 2b PARADIGM trial, the therapy showed a 36% slowdown in ALS progression and a 43% improvement in survival compelling outcomes in a field where treatment options are few and efficacy gains are hard-won. That performance is part of what’s drawing interest from the industry—and why a Canadian approval could serve as a powerful launchpad, both commercially and strategically. The Canadian ALS market alone could support $100–150 million in annual peak sales, according to company estimates. But what’s arguably more valuable is the opportunity to generate real-world data and establish market traction ahead of broader approvals, particularly in the U.S. and Europe. Investors likely won’t have to wait long for clarity. NeuroSense expects to receive official meeting minutes from Health Canada shortly and will update the market once eligibility is confirmed. If successful, the NDS filing and Phase 3 launch would likely follow. In a sector defined by long timelines and uncertain outcomes, NeuroSense now finds itself in a rare position, with validated clinical data, regulatory momentum, and a pending global partnership that could reprice the story entirely. The next few months may determine whether PrimeC becomes not only a commercial product, but also a cornerstone of a much larger biotech success. ‎ Read more from the Finance Herald The New Digital Iron Curtain: How the EU’s Digital Services Act Threatens American Free Speech The Nobel Dilemma: Should Trump Embrace or Reject a Controversial Legacy? New York City’s Political Revolution: Zohran Mamdani’s Far-Left Vision Sparks National Debate States Challenge Trump Administration’s Funding Cuts in Major Legal Battle Heating Up: Power Crisis Strikes the Eastern U.S. Amid Record Temperatures ‎ ‎ * ⚠︎ Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from NeuroSense Therapeutics Ltd. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. We are not responsible for any price targets that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details ‎ media.globalmarkets@gmail.com

June 26, 2025 09:24 AM Eastern Daylight Time

Image

This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret

VentureBlock

With 3X Its Market Cap in Military Grants and Analyst Targets of $15-16, This Military-Backed Phage Therapy Pioneer Trades at Just $0.48 (NYSE: PHGE)*, all while their competitor (NYSE: ARMP) trades at over 6X ‎‎ BiomX Inc. (NYSE: PHGE)* presents an unusual situation in biotech: a company trading at just below a $13 million market cap that has secured $40 million in non-dilutive funding from the U.S. Defense Health Agency. This Pentagon backing, administered through the Naval Medical Research Command, has enabled the company to advance its bacteriophage therapies without the typical shareholder dilution that plagues early-stage biotechs. The military’s interest centers on antibiotic-resistant infections emerging from conflict zones. According to BiomX CEO Jonathan Solomon, medical personnel are “seeing soldiers coming out of the Ukraine war with extremely antibiotic-resistant infections.” This real-world crisis has elevated phage therapy, using viruses that naturally kill bacteria, from scientific curiosity to strategic priority. ‎ The Numbers Behind the Story BiomX’s recent Phase 2 DANCE trial results help explain the military’s confidence. The study of 41 patients with diabetic foot osteomyelitis showed: Statistically significant reduction in ulcer size by week 12 (p=0.046) Greater than 40% difference in healing between treatment and placebo groups by week 10 Significant improvement in ulcer depth at week 13 (p=0.048) Significant reduction in ulcer area expansion (p=0.017) No serious adverse events These results matter because diabetic foot infections lead to approximately 160,000 amputations annually in the U.S., creating an $8 billion healthcare burden. The same Staphylococcus aureus bacteria causing these civilian amputations also complicates combat wound care, making BX211 a dual-use technology. ‎ Beyond Military Applications While defense funding validates the technology, BiomX’s commercial opportunity spans multiple indications. The company’s BX004 program for cystic fibrosis demonstrated that 14.3% of patients (3 out of 21) completely cleared chronic Pseudomonas aeruginosa lung infections after 10 days of treatment, compared to 0% in the placebo group. One patient had carried the infection for 35 years before achieving clearance. BiomX estimates addressable markets of $2.5 billion globally for diabetic foot infections and $1.6 billion for cystic fibrosis. The FDA has already granted Fast Track and Orphan Drug designations to BX004, potentially accelerating the regulatory pathway. ‎ The Market Disconnect & Opportunity Current analyst coverage reveals a striking valuation gap. H.C. Wainwright maintains a Buy rating with a $15 price target, while Laidlaw & Company also rates the stock Buy with a $16 target. From recent trading levels around $0.52, these targets represent potential upside of approximately 2,800-2,900%. Laidlaw analyst Yale Jen called the BX211 Phase 2 results “an absolutely positive surprise,” characterizing the asset as “high value and clinically de-risked.” H.C. Wainwright’s assessment emphasizes the program’s advancement toward “important regulatory discussions” with the FDA. The disconnect becomes even more apparent when compared to peers. Armata Pharmaceuticals (NYSE: ARMP), the only other publicly-traded pure-play phage therapy company, trades at approximately $70 million, more than 5X BiomX’s valuation despite having just one clinical program compared to BiomX’s two Phase 2 assets and $40 million in military backing. ‎ Understanding the Opportunity Several factors contribute to BiomX's current valuation disconnect: Non-dilutive funding advantage: The $40 million military grant has funded clinical development without issuing new shares, preserving value for existing shareholders. Limited competition: No new drugs have been approved specifically for diabetic foot osteomyelitis in over 20 years, giving BiomX potential first-mover advantage in a massive unmet need. Impressive platform validation: Success in two separate indications (DFO and cystic fibrosis) demonstrates the broader applicability of the phage platform. Near-term catalysts: Phase 2b results for BX004 expected in Q1 2026, FDA meetings for BX211 Phase 2/3 design, and potential additional military funding or partnerships. ‎ The Broader Context BiomX operates within converging megatrends. The Biden administration has proposed $88.2 billion for biodefense over five years, while organizations like DARPA and ARPA-H are investing hundreds of millions in next-generation antimicrobials. NATO has formed a task force specifically to reintroduce phage therapy in military medicine. The company’s ability to address both military and civilian needs positions it uniquely as governments worldwide recognize antimicrobial resistance as a national security threat. With China producing 80-90% of antibiotic raw materials, supply chain vulnerabilities add urgency to developing alternative therapies. ‎ Looking Ahead BiomX’s story combines validated science, government backing, and massive market opportunities with a market cap that appears disconnected from fundamental value. The $40 million in Pentagon funding alone exceeds the company’s current market valuation by 3X, while clinical success and analyst targets suggest significant upside potential. As the company advances toward Phase 2/3 trials for BX211 and awaits Phase 2b results for BX004, the convergence of military necessity and civilian healthcare needs could transform this overlooked biotech into a key player in humanity’s fight against antibiotic-resistant infections. ‎ This article was syndicated from VentureBlock. ‎ ‎ Recent News Highlights BiomX: BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) ‎ ‎ * ⚠︎ Paid Advertisement Disclaimer: This content is a paid advertisement. Wall Street Wire has received compensation from BiomX Inc. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. We are not responsible for any price targets that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details ‎ media.globalmarkets@gmail.com

June 26, 2025 08:31 AM Eastern Daylight Time

Image

1 2 3 4 5 ... 549